TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9247759

Group type: EXPERIMENTAL
Intervention: Perindopril (+/‐ indapamide)
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Matching placebo(s)
Number of subjects: 6000
Study: 8093267

Group type: EXPERIMENTAL
Intervention: External hip protectors
Number of subjects: 447

Group type: COMPARATOR
Intervention: Control group (no hip protectors)
Number of subjects: 447
Study: 3954127

Group type: EXPERIMENTAL
Intervention: Isoflurane (N = 8)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Halothane (N = 7)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Comparison of isoflurane and halothane
Number of subjects: 15
Study: 11445756

Group type: EXPERIMENTAL
Intervention: Creatine (0.3 g.kg(‐1) Cr monohydrate for 7 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31582354

Group type: EXPERIMENTAL
Intervention: FCR chemoimmunotherapy
Number of subjects: 210
Study: 29458447

Group type: EXPERIMENTAL
Intervention: Self-monitoring urinary salt excretion using a self-measuring device for 4 weeks
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (urine salt excretion measured but results not disclosed)
Number of subjects: 78
Study: 26804607

Group type: EXPERIMENTAL
Intervention: Clinical factors alone
Number of subjects: 2219

Group type: EXPERIMENTAL
Intervention: Clinical plus echocardiographic findings
Number of subjects: 2219
Study: 25373314

Group type: EXPERIMENTAL
Intervention: D‐PBL (decision‐PBL)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Linear PBL
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: D‐PBL
Number of subjects: 81
Study: 22578037

Group type: EXPERIMENTAL
Intervention: Twelve-Step facilitation (TSF)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Integrated cognitive-behavioral therapy (ICBT)
Number of subjects: 209
Study: 20082054

Group type: EXPERIMENTAL
Intervention: MAVIS nutrition trial
Number of subjects: 801
Study: 17641254

Group type: EXPERIMENTAL
Intervention: Topiramate 50 mg/day
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Topiramate 400 mg/day
Number of subjects: 470
Study: 15938536

Group type: EXPERIMENTAL
Intervention: Combination of lisinopril with indapamid
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combination of egilok+hypothiaside
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combination of diroton+indap
Number of subjects: 150

Group type: COMPARATOR
Intervention: Combination of cordipin-retard+hypothiaside
Number of subjects: 150

Group type: COMPARATOR
Intervention: Combination of renitek-hypothiaside
Number of subjects: 150
Study: 12117883

Group type: EXPERIMENTAL
Intervention: L-NMMA 4 mg/kg/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-NMMA 8 mg/kg/h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9935002

Group type: EXPERIMENTAL
Intervention: Pacemaker
Number of subjects: 54

Group type: COMPARATOR
Intervention: No Pacemaker
Number of subjects: 54
Study: 8697055

Group type: EXPERIMENTAL
Intervention: Ephedrine + Caffeine (E+C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2349371

Group type: EXPERIMENTAL
Intervention: 0.4 mg naloxone intravenous injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 623171

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 0
Study: 30856641

Group type: EXPERIMENTAL
Intervention: Cemented lithium disilicate crown on a customized zirconia abutment (CEM)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Screw-retained crown with a directly veneered zirconia abutment (SCREW)
Number of subjects: 34
Study: 29390014

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of AL and ASAQ
Number of subjects: 0
Study: 26755382

Group type: EXPERIMENTAL
Intervention: Tocilizumab (40 mg) + 1-2 mL of 0.5% bupivacaine
Number of subjects: 63

Group type: COMPARATOR
Intervention: 0.5% bupivacaine (control group)
Number of subjects: 63
Study: 25266967

Group type: EXPERIMENTAL
Intervention: Arthroscopic Sub‐Acromial Decompression (ASAD)
Number of subjects: 73
Study: 23084166

Group type: EXPERIMENTAL
Intervention: Extended Enhancing Resiliency Amongst Students Experiencing Stress (ERASE‐Stress) - a manualized active 16‐session intervention
Number of subjects: 154

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 154
Study: 20110402

Group type: EXPERIMENTAL
Intervention: GH treatment at a dose of 2 mg/m(2) per day until the onset of puberty for at least 2 years.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 40
Study: 17950163

Group type: EXPERIMENTAL
Intervention: Stomp Out Smokes (SOS) intervention for 24 weeks
Number of subjects: 70
Study: 16392436

Group type: EXPERIMENTAL
Intervention: Pumpan® (3 × 10 drops daily for 6 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pumpan® and Placebo
Number of subjects: 0
Study: 14579632

Group type: EXPERIMENTAL
Intervention: Intervention through interviews conducted by Clinical Pastoral Education residents using the Brief Depression Scale, UCLA Loneliness Scale, and Index of Core Spiritual Experience.
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Intervention through interviews assessing spirituality.
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Intervention through interviews assessing ability to venture out of the house and family relationships.
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Intervention through interviews assessing sense of meaning or purpose in life.
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Intervention through interviews assessing spirituality demographics.
Number of subjects: 118
Study: 11010944

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 298

Group type: COMPARATOR
Intervention: Nonpregnant US women
Number of subjects: 298
Study: 8858322

Group type: EXPERIMENTAL
Intervention: Early feeding (3 hours after PEG placement)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Delayed feeding (24 hours after PEG placement)
Number of subjects: 41
Study: 1284345

Group type: EXPERIMENTAL
Intervention: Isovolemic hemodilution (IHD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (routine therapy only)
Number of subjects: 20
Study: 6337663

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 10

Group type: COMPARATOR
Intervention: Choline magnesium trisalicylate
Number of subjects: 10
Study: 30888835

Group type: EXPERIMENTAL
Intervention: HCL AP therapy with the Control-IQ system
Number of subjects: 24

Group type: COMPARATOR
Intervention: SAP therapy with remote monitoring
Number of subjects: 24
Study: 29454311

Group type: EXPERIMENTAL
Intervention: Mepitel Film (Arm A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (Arm B)
Number of subjects: 0
Study: 27299483

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 2.5 mg
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 83
Study: 24972708

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 22864520

Group type: EXPERIMENTAL
Intervention: Adrenalized infraclavicular lidocaine 2% 10 ml + ropivacaine 0.75% 20 ml ('long acting', n=90)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Adrenalized infraclavicular lidocaine 1.5% 30 ml + long-acting distal median, radial, and ulnar nerve blocks ('short acting', n=87)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Short acting group
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Long acting group
Number of subjects: 177
Study: 20143047

Group type: EXPERIMENTAL
Intervention: Drug therapy alone
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Combined drug and behavioral therapy
Number of subjects: 307

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 307
Study: 17650661

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment (5‐10 mA, 80‐100 Hz, 30 min stimulation, once daily for 10 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cetirizine (10 mg/times, t.i.d, peros)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 100
Study: 16037237

Group type: EXPERIMENTAL
Intervention: Dihydroxyacetone (DHA) followed by naphthoquinone, applied topically at bedtime
Number of subjects: 30

Group type: COMPARATOR
Intervention: 3% DHA topically (previous studies)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dihydroxyacetone (DHA) followed by naphthoquinone
Number of subjects: 30
Study: 12234851

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied one time per week
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied two times per week
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied three times per week
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream (all dosing regimens)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 124
Study: 9612628

Group type: EXPERIMENTAL
Intervention: Contrast medium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isovolemic hemodilution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various antibiotics
Number of subjects: 0
Study: 7817332

Group type: EXPERIMENTAL
Intervention: Benzodiazepine (lormetazepam, 2 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2461823

Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30729456

Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg bid
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 30025519

Group type: EXPERIMENTAL
Intervention: Minimally invasive direct anterior approach (DAA)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Direct transgluteal lateral approach
Number of subjects: 123
Study: 27021357

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention package (GNS-led staff education, facility benchmarking, GNS resident review, multidisciplinary discussion)
Number of subjects: 1998

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention package
Number of subjects: 1998

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1998
Study: 25566618

Group type: EXPERIMENTAL
Intervention: Bushen Huoxue Sanyu Decoction (BHSD)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Mirena
Number of subjects: 70
Study: 22233522

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) conversion regimen
Number of subjects: 607

Group type: COMPARATOR
Intervention: Calcineurin inhibitors (CNI) continuation
Number of subjects: 607
Study: 20107216

Group type: EXPERIMENTAL
Intervention: Internal tocodynamometry
Number of subjects: 1456

Group type: COMPARATOR
Intervention: External monitoring
Number of subjects: 1456
Study: 17643617

Group type: EXPERIMENTAL
Intervention: Stentless xenograft aortic valve replacement
Number of subjects: 223

Group type: COMPARATOR
Intervention: Conventional stented xenograft aortic valve replacement
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 223
Study: 16245354

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) for 5 years (20 mg/day)
Number of subjects: 1901

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) for 2 years (20 mg/day)
Number of subjects: 1901
Study: 11886196

Group type: EXPERIMENTAL
Intervention: Silver-impregnated central venous catheter (CVC)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Commercially available central venous catheter (CVC)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Both groups (SC and CC)
Number of subjects: 157
Study: 9808930

Group type: EXPERIMENTAL
Intervention: Cognitive psychotherapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Family psychotherapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy
Number of subjects: 100
Study: 7660449

Group type: EXPERIMENTAL
Intervention: 6 mg/kg DEC once daily for 12 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 mg/kg DEC given 3 times daily for 12 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All 3 treatment regimens (6 mg/kg once daily, 2 mg/kg three times daily, and unspecified third regimen)
Number of subjects: 0
Study: 2913493

Group type: EXPERIMENTAL
Intervention: Outpatient detoxification with decreasing doses of oxazepam
Number of subjects: 164

Group type: COMPARATOR
Intervention: Inpatient detoxification with oxazepam and rehabilitation treatment
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Outpatient detoxification
Number of subjects: 164

Group type: COMPARATOR
Intervention: Inpatient detoxification
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 164
Study: 972787

Group type: EXPERIMENTAL
Intervention: Oral riboflavin with blue light energy of 6-7 muW/cm2
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group with blue light energy of 8-10 muW/cm2
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Riboflavin-treated infants receiving less energy than control (6-7 muW/cm2)
Number of subjects: 24
Study: 7303703

Group type: EXPERIMENTAL
Intervention: 0.3 mg beta‐methyldigoxin (Lanitop) daily, orally
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.4 mg beta‐acetyldigoxin (Novodigal) daily, orally
Number of subjects: 24

Group type: COMPARATOR
Intervention: beta‐methyldigoxin
Number of subjects: 24

Group type: COMPARATOR
Intervention: beta‐acetyldigoxin
Number of subjects: 24
Study: 30496003

Group type: EXPERIMENTAL
Intervention: Greening intervention
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Mowing and trash cleanup intervention
Number of subjects: 541

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 541
Study: 28889792

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nivolumab plus ipilimumab vs. ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nivolumab vs. ipilimumab
Number of subjects: 0
Study: 25204200

Group type: EXPERIMENTAL
Intervention: Antismoking ad targeting specific peer crowds
Number of subjects: 239
Study: 24075842

Group type: EXPERIMENTAL
Intervention: Discharge management intervention using nurse care managers
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (standard discharge process)
Number of subjects: 60
Study: 22053754

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 36

Group type: COMPARATOR
Intervention: No chewing gum (Control)
Number of subjects: 36
Study: 19196913

Group type: EXPERIMENTAL
Intervention: Low volume/moderate intensity (12 miles/wk, 1,200 kcal/wk at 40-55% Vo(2peak), 200 min exercise/wk)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: High volume/vigorous intensity (20 miles/wk, 2,000 kcal/wk at 65-80% Vo(2peak), 200 min/wk)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Low volume/vigorous intensity (12 miles/wk, 1,200 kcal/wk at 65-80% Vo(2peak), 125 min/wk)
Number of subjects: 3
Study: 18167644

Group type: COMPARATOR
Intervention: Upper trunk SAT volume (highest tertile)
Number of subjects: 1184

Group type: COMPARATOR
Intervention: VAT volume (highest tertile)
Number of subjects: 1184
Study: 15078004

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg b.i.d. x 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amoxicillin (1 g t.i.d. x 7 days)
Number of subjects: 0
Study: 11453959

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 12

Group type: COMPARATOR
Intervention: Human regular insulin
Number of subjects: 12
Study: 9919896

Group type: EXPERIMENTAL
Intervention: Itraconazole 400 mg daily for 1 week
Number of subjects: 135

Group type: COMPARATOR
Intervention: Itraconazole 100 mg daily for 4 weeks
Number of subjects: 135
Study: 8311214

Group type: EXPERIMENTAL
Intervention: Intra-articular morphine (1 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intra-articular bupivacaine with adrenaline
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of morphine and bupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3138057

Group type: EXPERIMENTAL
Intervention: Vamin 14 infusion
Number of subjects: 8
Study: 31627213

Group type: EXPERIMENTAL
Intervention: Viewing a more attractive painting on the previous trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 s exposure times
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 250 ms exposures followed by a mask
Number of subjects: 0
Study: 28314613

Group type: EXPERIMENTAL
Intervention: Ultra-low dose (ULD) protocols (I: 100kVp/50 mAs, II: 100kVp/75 mAs, III: 100kVp/100 mAs, IV: 120kVp/100 mAs)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low dose (LD) protocols (I: 100kVp/75 mAs, II: 100kVp/100 mAs, III: 100kVp/150 mAs, IV: 120kVp/150 mAs)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: K-IMR CR 1 in the ULD group
Number of subjects: 40
Study: 26074391

Group type: EXPERIMENTAL
Intervention: Pallidal deep brain stimulation (DBS)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham control (not explicitly detailed in the abstract)
Number of subjects: 13
Study: 23504379

Group type: EXPERIMENTAL
Intervention: Minimal intervention (MIN)
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Intensive intervention (INT)
Number of subjects: 881

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 881
Study: 21542427

Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 140

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 140
Study: 20001809

Group type: EXPERIMENTAL
Intervention: Hepatic venous outflow occlusion (HVOO)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Non-HVOO
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: HVOO
Number of subjects: 39
Study: 16731321

Group type: EXPERIMENTAL
Intervention: Cisatracurium plus 3 mg/kg lidocaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (3 mg/kg lidocaine diluted with saline)
Number of subjects: 40
Study: 15256690

Group type: EXPERIMENTAL
Intervention: Acute Rhodiola rosea intake (200 mg extract containing 3% rosavin + 1% salidroside)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acute Rhodiola rosea intake (200 mg extract)
Number of subjects: 24
Study: 10502865

Group type: EXPERIMENTAL
Intervention: Turner and Engle operation span task
Number of subjects: 33
Study: 8858190

Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dopamine agonists (pergolide, bromocriptine, cabergoline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Catechol-O-methyltransferase inhibitors (tolcapone, entacapone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levodopa therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selegiline therapy
Number of subjects: 0
Study: 1862015

Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen controlled-release tablet (CRT)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 1200 mg ibuprofen controlled-release tablet (CRT)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 6869899

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg orally the evening before and 300 mg intramuscularly between 1 and 3 h preoperatively)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Antacid (30 ml of Mylanta-II orally on both occasions)
Number of subjects: 126
Study: 31773430

Group type: EXPERIMENTAL
Intervention: Web-Based Intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Email-Counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29930429

Group type: EXPERIMENTAL
Intervention: Vacuum-formed retainers at night (experimental group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Routine examination (control group)
Number of subjects: 46
Study: 26945451

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24499830

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 26
Study: 23285647

Group type: EXPERIMENTAL
Intervention: Octrestatin injected perioperatively
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (no octrestatin applied)
Number of subjects: 105
Study: 18838500

Group type: EXPERIMENTAL
Intervention: Dopamine agonist (pramipexole 0.5 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dopamine antagonist (sulpiride 400 mg)
Number of subjects: 20
Study: 18507543

Group type: EXPERIMENTAL
Intervention: Closed loop stimulation (CLS)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Accelerometer-based pacing
Number of subjects: 400
Study: 15963090

Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 12904518

Group type: EXPERIMENTAL
Intervention: Estrogen therapy with micronized 17beta‐estradiol alone
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol plus sequentially administered medroxyprogesterone acetate
Number of subjects: 226

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 226
Study: 10534213

Group type: EXPERIMENTAL
Intervention: Severity of GERD
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: GERD patients without comorbidity
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Study patients
Number of subjects: 268